Brightstar

Brightstar Therapeutics is a biotechnology company focused on providing innovative therapeutic solutions for patients with corneal and ocular surface diseases, improving clinical outcomes and quality of life. It offers a long-term solution for persistent epithelial defects and partial limbal stem cell deficiency through its late-stage corneal graft, BrightMEM. The allograft promotes durable regeneration of the corneal epithelium while providing protection for the underlying stromal tissue.